An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

Cell

Volumn 106, Issue 5, 2001, Pages 539-549

  Rose, Nina F ^a   Marx, Preston A ^b,c   Luckay, Amara ^c   Nixon, Douglas F ^d   Moretto, Walter J ^d   Donahoe, Sean M ^d   Montefiori, David ^e   Roberts, Anjeanette ^a   Buonocore, Linda ^a   Rose, John K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; VIRUS VECTOR;

ARTICLE; CELL LOSS; CELL PROTECTION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SEROTYPE; T LYMPHOCYTE; VESICULAR STOMATITIS VIRUS; VIRUS LOAD;

AIDS VIRUS; ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; MACACA MULATTA; RNA VIRUSES; VESICULAR STOMATITIS VIRUS;

EID: 17944369239     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(01)00482-2     Document Type: Article

References (45)

1. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
2. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
3. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency type 1 infection
4. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
5. A vaccine for HIV type 1: The antibody perspective
6. T cell receptor V beta repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus
7. Characterization of primary isolate-like variants of simian-human immunodeficiency virus
8. Protective effects of a live attenuated SIV vaccine with a deletion in the nef
9. + T cell responses in macaques infected with simian immunodeficiency virus
10. Human infection with the virus of vesicular stomatitis during an epizootic
11. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: High-level production of virus-like particles containing HIV envelope
12. Eradication of vaccine-preventable diseases
13. + cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins
14. Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV)
15. + lymphocyte depletion in rhesus monkeys
16. + T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques
17. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus
18. Generation of mucosal cytotoxic T cells against soluble protein by tissue-specific environmental and costimulatory signals
19. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
20. High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses
21. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex
22. Recombinant vesicular stomatitis viruses from DNA
23. Preferential localization of effector memory cells in nonlymphoid tissue
24. Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1
25. Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry
26. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
27. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
28. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay
29. + T cells with a predominant V beta usage during the primary immune response to HIV
30. The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus
31. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
32. Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain
33. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein
34. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge
35. Attenuated vesicular stomatitis viruses as vaccine vectors
36. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1
37. + T cell responses associated with control of viremia
38. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies
39. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles
40. Minimal conserved sequences promote stable expression of a foreign gene in vesicular stomatitis virus
41. Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus
42. Ecologic studies of vesicular stomatitis virus. I. Prevalence of infection among animals and humans living in an area of endemic VSV activity
43. Rhabdoviridae: The viruses and their replication
44. Cell-mediated immunity to vesicular stomatitis virus infections in mice